News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

CTD Holdings, Inc. Moves Ahead on Research Park Project



6/12/2009 9:57:56 AM

HIGH SPRINGS, FL--(Marketwire - June 12, 2009) -

CTD Holdings, Inc. (OTCBB: CTDH) (FRANKFURT: CDJ) announced that ViStra Growth Partners, Inc. (VGP), the newly created subsidiary of CTD, has agreed to present a preliminary project plan to the CTD board of directors by year end, 2009, for the proposed "Joszef Szejtli Cyclodextrin Research Park." Mr. Louis Weltman, the President/CEO of VGP, has considerable experience with commercial property development for such purposes. Rick Strattan, the Chairman/CEO of CTDH, stated that, "This project has been on the back burner at CTDH ever since we paid off the mortgage on the 40 acre corporate site in 2007. The convergence of CTDH's work with Chris Hempel to get Trappsol® HPB into a compassionate use study for her twin girls with Niemann-Pick disease, a form of childhood Alzheimer's, and working with the expertise of Lou Weltman and his knowledge of 501(c)3 organizations has really crystallized for me what the mission of the Research Park will be."

Mr. Strattan continues, "Chris Hempel has done more in the last 18 months to introduce the worldwide public and regulatory agencies to the amazing properties of Cyclodextrins, than the entire industry has been able to do in the last 20 years."

Ms. Hempel's exploits, efforts and successes are available on the web at www.addiandcassi.com and www.webofhope.com.

About CTD Holdings, Inc.

The company is the one-stop shop, business to business facilitator of commercial and research applications of cyclodextrins. With its branded Trappsol® and Aquaplex® product offerings, CTDH scientists coordinate the development of commercial products for use in the pharmaceuticals, foods, hazardous waste treatment, and cosmetics industries, just to name a few of the industries which endeavor to put non water-soluble ingredients into water-based formulations. More recently CTDH has worked, in an advisory capacity, on the benefits and application of Cyclodextrins as a treatment for Niemann-Pick disease, a debilitating childhood disease often associated with Alzheimer's. CTDH was founded in 1990 as a Florida corporation and became a public company in 1994. Additional information on the Company can be found on the Company's website: www.cyclodex.com

This news release contains "forward-looking statements" that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. You are cautioned that such statements are subject to risks and uncertainties that could cause future circumstances, events or results to differ materially from those projected in the forward-looking statements. CTDH complies with the regulations and time lines mandated by the SEC in the filing of its financial reports; these filings also contain forward-looking statements. The above forward-looking statements are made as of the date above; CTD Holdings, Inc. accepts no specific responsibility for updating such statements.


Contact:
Rick Strattan
CEO
386-454-0887


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES